Biogelx and 3DBS partner to bring complete bioprinting solutions to Brazilian market
Scottish bioprinting company Biogelx has announced a partnership with 3D Biotechnology Solutions (3DBS), a Brazil-based manufacturer of bioprinting and electrospinning technologies. The companies will work together, combining their respective expertise to offer complete, tissue-specific bioprinting solutions for the Brazilian market. The partnership will also see 3DBS distributing Biogelx-INK bioprinting materials in the region.
Biogelx is an interesting company within the bioprinting sphere: it is one of the leading developers and producers of synthetic peptide hydrogel materials. The company recently introduced a series of hydrogel-based bioinks, Biogelx-INKs, that are not only biocompatible and extremely versatile but also easily and reliably printable. The reliability, says the company, is thanks to the synthetic nature of the hydrogels.
Through its partnership with 3DBS, Biogelx is moving ahead with its international growth strategy in Brazil, aiming to bring its products to public and private research institutions as well as universities and research consortiums.
“Over the past six years, we have built a reputation as the leading synthetic 3D cell culture scaffold brand,” said Sandy Bulloch, Director of Strategic Alliances of Biogelx. “Working with 3DBS allows us to transform how we scale our business to provide a complete bioprinting platform for multiple cell culture applications. This collaboration will accelerate the pace of our bioprinting innovation to generate the next generation of 3D tissue models.
3DBS, for its part, specializes in tissue engineering and is helping to shape the future of regenerative medicine with its innovative bioprinting products, including the Reactor, Genesis and other 3D bioprinter models. The company’s overarching goal is to provide tissue generating technologies to enable the construction of living human tissues.
“At 3DBS, our vision is to be a significant contributor in the construction of the future of regenerative medicine,” explained Pedro Massaguer, PhD, Co-Founder of 3DBS. “By enabling customers to work with Biogelx-INKs using our bioprinters such as Genesis, Reactor or Octopus, we are getting one step closer to our revolutionary goal. Together, we have the opportunity to deliver more tissue-specific like constructs for applications in regenerative medicine and drug discovery.”
The collaboration between the two bioprinting companies will not only aim to provide “complete, tissue-specific bioprinting solutions” but to enable Brazilian researchers to reduce lead times and costs by purchasing Biogelx-INKs directly from the new Brazilian distributor.
